Abemaciclib + LY3023414 + Gemcitabine + Capecitabine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Ductal Adenocarcinoma
Conditions
Pancreatic Ductal Adenocarcinoma
Trial Timeline
Jan 12, 2017 → Nov 9, 2018
NCT ID
NCT02981342About Abemaciclib + LY3023414 + Gemcitabine + Capecitabine
Abemaciclib + LY3023414 + Gemcitabine + Capecitabine is a phase 2 stage product being developed by Eli Lilly for Pancreatic Ductal Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02981342. Target conditions include Pancreatic Ductal Adenocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02981342 | Phase 2 | Completed |
Competing Products
20 competing products in Pancreatic Ductal Adenocarcinoma